APhA and ASHP reps met with FDA Associate Commissioner for Health Affairs Nightingale and staff Aug. 30 to discuss a new draft of the book. APhA commented that the Legend should reflect changes in pharmacy practice, i.e., repacking, and be changed in tone to more specifically address its professional audience
You may also be interested in...
In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.
Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.
Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.